What are the insurance criteria to cover a computed tomography (CT) scan of the abdomen with and without contrast of the adrenal glands in a patient with hyperandrogenism (elevated testosterone) to rule out malignancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Insurance criteria for covering a CT abdomen with and without contrast to evaluate the adrenal glands in a patient with elevated testosterone (not on testosterone therapy) typically requires documentation of significantly elevated testosterone levels along with clinical symptoms suggesting a possible adrenal malignancy, as recommended by the most recent guidelines 1. To meet the insurance criteria, the following conditions should be met:

  • Significantly elevated testosterone levels, well above the normal range, should be documented, as suggested by the guidelines for the diagnosis of adrenocortical carcinomas and malignant pheochromocytomas 1.
  • Clinical symptoms suggesting a possible adrenal malignancy, such as rapid onset of virilization, hirsutism, or other signs of androgen excess, should be documented.
  • The ordering physician should document the medical necessity by noting that the elevated testosterone is unexplained by other causes and that adrenal pathology, particularly adrenal carcinoma, needs to be excluded.
  • Additional supporting documentation may include:
    • Failed response to more conservative management
    • Family history of endocrine disorders
    • Other concerning clinical features The CT with both pre-contrast and post-contrast imaging is specifically requested because adrenal masses often require contrast enhancement for proper characterization, with washout calculations helping to distinguish between benign adenomas and malignant lesions, as indicated by the American College of Radiology Appropriateness Criteria 1. Insurance approval is more likely when the ordering physician clearly documents that the imaging is necessary to rule out a potentially life-threatening condition that would significantly alter patient management, as emphasized by the guidelines for the management of patients with metastatic non-small-cell lung cancer 1.

From the Research

Insurance Criteria for CT Abdomen with and without Contrast of Adrenals

  • The provided studies do not directly address the insurance criteria for covering CT abdomen with and without contrast of adrenals in patients with elevated testosterone levels 2, 3, 4, 5, 6.
  • However, the studies suggest that elevated testosterone levels may be associated with various health conditions, such as sleep disorders, urinary symptoms, and depression 2, and may also increase the risk of cardiovascular complications 3, 4.
  • In patients with elevated testosterone levels, imaging studies such as CT scans may be used to rule out malignancy or other underlying conditions 5.
  • The decision to cover CT abdomen with and without contrast of adrenals may depend on the individual patient's medical history, symptoms, and insurance policy 6.
  • It is essential to consult with a healthcare professional and review the specific insurance policy to determine the coverage criteria for CT abdomen with and without contrast of adrenals in patients with elevated testosterone levels.

Relevant Studies

  • A study published in 2022 found that elevated endogenous testosterone levels were not associated with significant clinical morbidity 2.
  • Another study published in 2017 reviewed the clinical applications of testosterone therapy and highlighted the potential risks and benefits of therapy 3.
  • A 2019 review discussed the association between testosterone replacement therapy and cardiovascular risk 4.
  • A 2001 study explored the diagnosis and localization of testosterone-producing ovarian tumors using imaging and biochemical evaluation 5.
  • A 2020 review compared the latest guidelines on testosterone therapy and highlighted the areas of agreement and disagreement 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.